PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer
Metrics: PDF 1245 views | HTML 4705 views | ?
Guangying Qi1,2,*, Yasusei Kudo3,*, Bo Tang4,*, Tian Liu1, Shengjian Jin1, Jing Liu1, Xiaoxu Zuo1, Sisi Mi1, Wenhuan Shao1, Xiaojuan Ma1, Takaaki Tsunematsu3, Naozumi Ishimaru3, Sien Zeng1, Masaaki Tatsuka5, Fumio Shimamoto2
1Department of Pathology and Physiopathology, Guilin Medical University, Guilin 541004, People’s Republic of China
2Department of Health Sciences, Prefectural University of Hiroshima, Hiroshima 734-8558, Japan
3Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8504, Japan
4Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin 541000, People’s Republic of China
5Department of Life Sciences, Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, Hiroshima 727-0023, Japan
*These authors have contributed equally to this work
Sien Zeng, e-mail: firstname.lastname@example.org
Masaaki Tatsuka, e-mail: email@example.com
Fumio Shimamoto, e-mail: firstname.lastname@example.org
Keywords: PARP6, Survivin, colorectal cancer, tumor suppressor, prognosis
Received: January 15, 2016 Accepted: February 15, 2016 Published: February 25, 2016
Poly (ADP-ribose) polymerases (PARPs) are enzymes that transfer ADP-ribose groups to target proteins and are involved in a variety of biological processes. PARP6 is a novel member, and our previous findings suggest that PARP6 may act as a tumor suppressor via suppressing cell cycle progression. However, it is still unclear that PARP6 function besides growth suppression in colorectal cancer (CRC). In this study, we examined tumor suppressive roles of PAPR6 in CRC cells both in vitro and in vivo. We found that PARP6 inhibited colony formation, invasion and migration as well as cell proliferation. Moreover, ectopic overexpression of PARP6 decreased Survivin expression, which acts as an oncogene and is involved in apoptosis and mitosis. We confirmed the inverse correlation between PARP6 and Survivin expression in CRC cases by immunohistochemistry. Importantly, CRC cases with downregulation of PARP6 and upregulation of Survivin showed poor prognosis. In summary, PARP6 acts as a tumor suppressor via downregulating Survivin expression in CRC. PARP6 can be a novel diagnostic and therapeutic target together with Survivin for CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.